Sees full year 2024 Revenue of approximately $29.4M represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately $5.6M is a notable improvement compared to $10.8M in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025…Full financial results for the year ended December 31, 2024 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav Infusion System, of approximately $8.3 million for the fourth quarter of 2024. This represents growth of approximately 44% versus the fourth quarter of 2023.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences announces publication of pre-clinical data
- TriSalus Announces Leadership Changes and New Incentive Program
- Roth expects ‘continued strong execution’ from TriSalus under new CFO
- Roth expects ‘continued strong execution’ TriSalus under new CFO
- TriSalus Life Sciences appoints James Young CFO, Richard Marshak CCO